Bajaj Healthcare Gets Listing Approval for 20,79,409 Equity Shares via Warrant Conversion

Bajaj Healthcare Limited has received listing approvals from the National Stock Exchange of India Limited (NSE) and BSE Limited for 20,79,409 equity shares of face value ₹5/- each. The approvals, communicated on May 06, 2026, pertain to shares allotted pursuant to the exercise of options for the conversion of convertible warrants into equity shares on a preferential basis. The development was disclosed by the company in accordance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The intimation was signed by Monica Tanwar, Company Secretary and Compliance Officer of Bajaj Healthcare Limited, on May 07, 2026.

Key Details of the Listing Approval

The following table summarises the key parameters of the approved listing:

Parameter:	Details
Number of Equity Shares:	20,79,409
Face Value:	₹5/- each
Issue Premium:	₹333/- per share
Distinctive Numbers:	31583253 to 33662661
Allottees:	Promoters and Non-Promoters
Basis of Allotment:	Preferential basis via warrant conversion
NSE Approval Reference:	NSE/LIST/54371
BSE Approval Reference:	LOD/PREF/RB/FIP/179/2026-27
Approval Date:	May 06, 2026

Exchange Approvals and Conditions

NSE granted in-principle approval for the listing of the 20,79,409 equity shares, subject to confirmation from depositories NSDL and CDSL regarding the credit of beneficiaries' accounts. BSE similarly granted listing approval and noted that trading approval will be issued only after the company fulfils specific conditions.

The conditions stipulated by BSE for trading approval include:

Submission of listing approval from NSE (if applicable)
Confirmation letters from NSDL/CDSL confirming credit of the shares to respective beneficiary accounts and admission to the depository system
Confirmation letters from NSDL/CDSL regarding lock-in of pre-preferential holding (if applicable)

Regulatory Compliance Requirements

BSE further directed Bajaj Healthcare to ensure compliance with Regulation 167 of the SEBI (Issue of Capital and Disclosure Requirements) Regulations. The exchange also noted that, as per Schedule XIX of the ICDR Regulations and SEBI circular no. SEBI/HO/CFD/PoD-2/P/CIR/2023/00094 dated June 21, 2023, the company is required to make an application for trading approval to the stock exchanges within seven working days from the date of grant of listing approval. Non-compliance with this requirement will attract fines as specified in the aforementioned SEBI circular.

Additionally, BSE indicated that in the event of a change exceeding two per cent of the total paid-up share capital, the company shall file the shareholding pattern in XBRL mode as required under Regulation 31(1)(c) of the SEBI LODR Regulations, 2015.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-0.93%	+4.60%	+7.01%	-24.00%	-36.16%	-7.27%

Bajaj healthcare has submitted its quarterly compliance certificate under SEBI regulations for the quarter ended March 31, 2026. The pharmaceutical company filed the mandatory documentation with both BSE and NSE on April 07, 2026, demonstrating its commitment to regulatory compliance.

Regulatory Compliance Filing

The compliance certificate was issued under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. This regulation requires companies to confirm proper handling of securities received from depository participants for dematerialization during each quarter.

Filing Details:	Information
Quarter Covered:	Q4FY26 (ended March 31, 2026)
Filing Date:	April 07, 2026
Reference Number:	BHL/STEX 1/2026-27
Filed By:	Monica Tanwar, Company Secretary

Certificate Confirmation

MUFG Intime India Private Limited, formerly known as Link Intime India Private Limited, serves as the company's registrar and transfer agent. The firm issued the compliance certificate on April 3, 2026, confirming several key regulatory requirements were met during Q4FY26.

The certificate confirms that:

Securities received from depository participants for dematerialization were properly accepted or rejected
All securities were listed on stock exchanges where previously issued securities are traded
Security certificates received for dematerialization were mutilated and cancelled after verification
Depository names were substituted in the register of members within prescribed timelines

Corporate Governance

Monica Tanwar, serving as Company Secretary and Compliance Officer, digitally signed and submitted the compliance documentation. The filing demonstrates Bajaj Healthcare's adherence to corporate governance standards and regulatory requirements for listed companies.

Stock Exchange Details:	Information
BSE Script Code:	539872
NSE Script Code:	BAJAJHCARE
Registrar:	MUFG Intime India Private Limited

This quarterly compliance filing represents standard regulatory practice for listed companies, ensuring transparency in securities handling and maintaining investor confidence through proper documentation and timely submissions to stock exchanges.